{"filing":{"accession_number":"0001420720-26-000010","cik":"0001420720","ticker":"IBIO","company_name":"iBio, Inc.","form":"8-K","filing_date":"2026-07-01","report_date":null,"primary_document":"ibio-20260701x8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1420720/000142072026000010/ibio-20260701x8k.htm"},"events":[{"id":15283,"run_id":13638,"accession_number":"0001420720-26-000010","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"iBio disclosed preclinical data from a non-human primate study of IBIO-610, a lead candidate antibody, demonstrating 98% inhibition of active Activin E through eight weeks and improved body composition when combined with semaglutide, representing a material clinical milestone supporting advancement toward human trials.","company_name":"iBio, Inc.","ticker":"IBIO","filing_date":"2026-07-01","form":"8-K","submitted_at":null,"items":[{"id":12984,"accession_number":"0001420720-26-000010","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"iBio disclosed preclinical data from a non-human primate study of IBIO-610, a lead candidate antibody, showing 98% inhibition of active Activin E through eight weeks and improved body composition when combined with semaglutide. This is a material operational/clinical milestone for a clinical-stage biotech company—positive preclinical efficacy data supporting advancement toward human trials—but does not fit the specific event types (earnings, M\u0026A, impairment, litigation, etc.). The disclosure is made under Item 7.01 (Regulation FD) and constitutes a material update on the company's pipeline progress that would affect a reasonable investor's assessment of the registrant's prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T11:38:17.658695+00:00","company_name":"","ticker":null,"filing_date":""},{"id":12985,"accession_number":"0001420720-26-000010","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"iBio disclosed preclinical data from an obese NHP study of IBIO-610, a lead candidate antibody, showing 98% inhibition of active Activin E through eight weeks and superior fat-selective weight loss when combined with semaglutide. This is a material operational/clinical milestone for a clinical-stage biotech company advancing a differentiated pipeline candidate, but does not fit the specific categories of earnings release, M\u0026A, impairment, litigation, or other named event types. The disclosure represents progress on a key product candidate that would affect investor assessment of the company's pipeline advancement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T11:38:17.658695+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":12984,"accession_number":"0001420720-26-000010","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"iBio disclosed preclinical data from a non-human primate study of IBIO-610, a lead candidate antibody, showing 98% inhibition of active Activin E through eight weeks and improved body composition when combined with semaglutide. This is a material operational/clinical milestone for a clinical-stage biotech company—positive preclinical efficacy data supporting advancement toward human trials—but does not fit the specific event types (earnings, M\u0026A, impairment, litigation, etc.). The disclosure is made under Item 7.01 (Regulation FD) and constitutes a material update on the company's pipeline progress that would affect a reasonable investor's assessment of the registrant's prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T11:38:17.658695+00:00","company_name":"iBio, Inc.","ticker":"IBIO","filing_date":"2026-07-01"},{"id":12985,"accession_number":"0001420720-26-000010","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"iBio disclosed preclinical data from an obese NHP study of IBIO-610, a lead candidate antibody, showing 98% inhibition of active Activin E through eight weeks and superior fat-selective weight loss when combined with semaglutide. This is a material operational/clinical milestone for a clinical-stage biotech company advancing a differentiated pipeline candidate, but does not fit the specific categories of earnings release, M\u0026A, impairment, litigation, or other named event types. The disclosure represents progress on a key product candidate that would affect investor assessment of the company's pipeline advancement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T11:38:17.658695+00:00","company_name":"iBio, Inc.","ticker":"IBIO","filing_date":"2026-07-01"}]}